CinDome Pharma, a Cincinnati, OH-based company dedicated to advancing a safe, chronic therapy for gastroparesis, raised $40M in Series B extension funding.
The round, which brought the total amount to $59M, included participation from Perceptive Advisors and CinRx Pharma.
The company intends to use the funds for the ongoing enrollment and evaluation of deudomperidone in the Phase 2 envision3D study in adults with diabetic gastroparesis and position itself for registrational trials.
CinDome is dedicated to advancing a safe, effective and tolerable treatment for people living with the devastating impact of chronic gastroparesis. Its deudomperidone (CIN-102) is an engineered formulation of well-known D2/D3 antagonist, domperidone, which is the first-line treatment for gastroparesis worldwide but not approved in the U.S.